Trial Profile
An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Erfonrilimab (Primary)
- Indications Malignant thymoma; Mesothelioma; Multiple myeloma; Nasopharyngeal cancer; Non-small cell lung cancer; Renal cancer; Small cell lung cancer; Solid tumours; Thoracic neoplasms; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 31 Jan 2021 Results (As of Jan 20, 2020; n=5) for safety,efficacy of KN046 in thoracic tumors, presented at the 2020 World Conference on Lung Cancer
- 31 May 2020 Results (n=29) of analysis assessing preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 21 Oct 2019 Planned End Date has been changed to 1 Apr 2020.